Sponsors (9)
The bill replaces short‑term regulatory ambiguity with clearer statutory rules and a path for civil claims, but does so by restricting importation and distribution, expanding liability, and freezing certain safety rules — trading broader access and regulatory flexibility for legal clarity and enforcement power.
Providers, pharmacies, hospitals, postal/courier workers, and patients face clearer, more predictable rules because the bill defines the covered drug, reverts to a known REMS, and sets explicit import/transport rules, reducing short‑term legal and administrative uncertainty.
Pregnant people prescribed the specified medication are explicitly covered under the statute, which proponents say protects their lawful access when the medication is prescribed and dispensed within the defined framework.
Patients who suffer physical or mental harm from covered abortion medications can pursue federal claims for compensatory and punitive damages (and attorney’s fees), and may also bring state‑law claims alongside federal suits.
Women and other patients will face substantially reduced access to mifepristone (through bans on importation, restrictions on telehealth distribution, and provider withdrawal), causing supply disruptions, increased barriers to abortion care, and a risk that some will seek unsafe alternatives.
Telehealth providers, pharmacies, and mail carriers face new federal civil liability exposure that will raise legal and compliance costs and may lead providers and pharmacies to stop offering services, further shrinking access.
Mandating reversion to a specific older REMS (June 2011) and naming a particular product reduces HHS’s flexibility to update safety monitoring or access controls based on new evidence or public‑health needs, potentially leaving patients with outdated risk‑mitigation rules and slowing emergency responses.
Based on analysis of 5 sections of legislative text.
Reinstates the June 2011 REMS for mifepristone, bans its importation, and creates a federal civil right to sue certain providers and importers for harms.
Official title: To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Introduced September 30, 2025 by Mary E. Miller · Last progress September 30, 2025
Reinstates a stricter FDA risk-management regime for mifepristone, bans its importation, and creates a new federal civil cause of action against certain providers and distributors. The bill directs the HHS Secretary to replace the current REMS for mifepristone with the version approved in June 2011 within 90 days, makes importing mifepristone illegal, and allows people harmed by use of specified abortion medications to sue telehealth providers, pharmacies, and importers/transporters for damages (effective 90 days).